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Abstract 
Sepsis is a life-threatening syndrome that occurred in patients with infection or injury. 
We detected the increase of endogenous lysophosphatidic acid (LPA) in cecal ligation 
and puncture (CLP)-induced sepsis. Administrating the inhibitor of autotaxin (ATX), 
the synthesis enzyme of LPA, induced severe sepsis with lower survival rate. While 
the intraperitoneal injection of LPA provided protection against sepsis-induced 
lethality. LPA injection induced the increase of IL-10, the prototype of 
anti-inflammatory cytokine, in CLP-subjected mice. ATX inhibitor administration 
reduced IL-10 in sepsis, and this ATX inhibitor-induced sever sepsis could be rescued 
by recombinant IL-10 protein injection. In vitro, LPA-enhanced IL-10 production 
from peritoneal macrophage. Macrophage depletion in vivo by clodronate also 
abrogated IL-10 in sepsis. Furthermore, peritoneal cavity cells that harvested from 
LPA5 KO mice, rather than other LPA receptor KO mice, canceled the response. The 
possibility of LPA5 as the involver receptor was further confirmed with high IL-10 
induced by LPA5 agonist and canceled LPA response by LPA5 antagonist. These 
results suggest the protective effects of ATX dependently produced endogenous LPA 
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in experimental sepsis through enhancing IL-10 induction from peritoneal 
macrophage mediated by LPA5 receptor. 
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Abbreviation  
ATX: autotaxin 
cDNA: complementary DNA 
CLP: cecal ligation and puncture 
ELISA: enzyme-linked immunosorbent assay 
FACS: fluorescence-activated cell sorting 
FCS: fetal calf serum 
GAPDH: glyceraldehydes 3-phosphate dehydrogenase 
GPCR: G protein-coupled receptor 
HT: hetero 
LC: liquid chromatography  
IL-10: interleukin-10 
IL-1β: interleukin-1 beta 
IFNγ: interferon gamma 
KO: knockout 
LPA: lysophosphatidic acid 
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LPC: lysophosphatidylcholine 
LPE: lysophosphatidylethanolamine 
LPG: lysophosphatidylglycerol 
LPI: lysophosphatidylinositol  
LysoPLD: lysophospholipase D 
LysoPS: lysophosphatidylserine  
LPS: lipopolysaccharide 
mRNA: message ribonucleic acid 
MS: mass spectrometry 
PBS: phosphate-buffered saline 
PCR: polymerase chain reaction 
PEI: polyethylenimine  
PSG: penicillin, streptomycin and glutamine 
S1P: sphingosin-1-phosphate 
TNF: tumor necrosis factor 
WT: wild-type  
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Chapter 1. General Introduction 
Sepsis, which is defined as a life-threatening organ dysfunction caused by a 
dysregulated host response to infection, is a leading cause of death wordwide1). 
Infection is the triggering event of sepsis. The host immune system is activated by the 
invading pathogen and remains aberrant even if the treatment of infection is 
successful2). Pathogenesis of sepsis involves many different components of host 
response, involving both excessive inflammation and immune suppression, and a 
failure of homeostasis2,3). Many efforts have been made to identify therapeutic targets 
for the treatment of sepsis. TNF, the pivotal mediator of sepsis, its monoclonal 
antibody could completely prevent the lethality of sepsis in animal models4), however, 
in sepsis patients, the effect is modest and there is variability between studies5), new 
therapies are still urgently needed. Targeting bioactive lipid mediators is one of the 
strategies. Lysophosphatidic choline (LPC), its therapeutic effects in experimental 
sepsis has been demonstrated6); however, the underlying mechanism remains unclear 
since it was proposed that LPC can prevent and treat sepsis by its receptor G2A6), but 
actually there is no evidence that LPC activate G2A as a receptor binding ligand 
	 8	
(Intro. Fig.1). We therefore wondered whether there is any other mechanism for 
explaining the therapeutic effects of LPC or not.  
 
Lysophosphatidic acid (LPA), one of the simplest lysophospholipids mediating 
diverse biological functions mainly by activating its six GPCRs (LPA1-LPA6)7,8), is 
mainly synthesized through hydrolyzing LPC by a secreted enzyme autotaxin (ATX)9) 
(Intro. Fig.2). LPA has various physiological and pathological functions including 
embryo implantation10), hair follicle formation11), angiogenesis12), bone13) and neural14) 
development. Protection of LPA against inflammation in vivo has also been proved in 
many animal models15-20) (Intro. Fig.3). We hypothesized that LPA that converted 
from LPC could be protective against sepsis. We investigated the effect of ATX 
inhibitor and LPA on cecal ligation and puncture (CLP), the mouse model of sepsis. 
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Nat Med. 2004 Feb;10(2):161-7. 
Intro. Figure 1. Therapeutic effects of LPC in sepsis. 
A. LPC provided protection against sepsis in mice 
model. B. LPC was reported to against sepsis through 
enhancing H2O2 production activity in neutrophils to 
increase bactericidal, which is mediated by G2A. 
However, there is no evidence that LPC activate G2A as 
a receptor binding ligand.  
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Intro. Figure 2. LPA and LPA receptors. Lysophosphatidic acid (LPA) was mainly 
synthesized from LPC by ATX, or from PA by PA-PLA1 α/β. LPA mediates various 
physio-pathological functions through its six receptors. 
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LPA increased mice survival to endotoxemia. 
 
 
 Mol Med. 14: 422-428, 2008. 
 
LPA protects endotoxin-induced lung Injury 
 
      JBC 284: 24123-24132, 2009 
 
 
LPA2 knockout mice exacerbated CLP induced lung injury.  
 
   J Aller Ther S4:	2155-6121, 2012 
 
 
Intro. Figure 3. Protection of LPA against inflammation in many animal models. 
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Chapter 2. Materials and Methods 
2.1. Reagents 
1-Oleoyl (18:1)-LPA, 1-Oleoyl (18:1)-LPC and 1-Myristoyl (14:0)-LPC were 
purchased from Avanti Polar Lipids Inc. LPA and LPA analogues (T series 
compounds) were dissolved in PBS containing 0.1% fatty acid free BSA (sigma) and 
stocked at -20°C. ATX inhibitor (ONO-8430506) was kindly provide by ONO 
Pharmaceutical Co. (Japan). Lipopolysaccharide from Escherichia coli 055:B5 was 
obtained from Sigma. Clophosome®-A-Clodronate Liposomes (Anionic) was 
obtained from FormuMa. LPA5 receptor antagonist (TC LPA5 4) was obtained from 
Tocris Bioscience.  
 
2.2. Experimental animal model 
Cecal ligation and puncture (CLP)-induced sepsis 
C57BL6/J mice were purchased from Japan SLC Inc. Adult male mice (8-12 weeks) 
were anesthetized by intraperitoneally administration of cocktail (M/M/B; 0.3 mg/kg 
of medetomidine, 4.0 mg/kg of midazolam, and 5.0 mg/kg of butorphanol). A small 
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midline abdominal incision was made. Then the cecum was exposed and ligated at 1.0 
cm from the end of cecum with a 6-0 silk suture and punctured twice with a 19G 
needle. The punctured cecum was then squeezed to expose a small amount of its 
content and repositioned to the peritoneal cavity. Abdomen was closed with double 
sutures and mice were resuscitated with 0.6 mg/kg atipamezole i.p.. After surgery, 
mice were fed ad libitum and the survival was monitored every 12 h. ATX inhibitor 
treated mice were orally administrated with ONO-8430506 dissolved in 0.5w/v% 
Methyl Cellulose (Wako Pure Chemical Co.) at the dose of 100 mg/kg body weight, 
just before CLP surgery and once a day after surgery for 4 days. 18:1 LPA (1 mg/kg 
body weight) treated mice were intraperitoneally injected 5 times at 6 h, 12 h, 24 h, 36 
h and 48 h after CLP. Mouse IL-10 recombinant was injected once subcutaneously 6 
h after CLP surgery. For sampling of peritoneal fluid, CLP-subjected mice were 
sacrificed after the timing indicated in each experiment and washed the peritoneal 
cavity with 1 mL sterile PBS following a gentle massage, then collected by pipette to 
1.5 mL tubes. After centrifugation at 300×g for 5 min, the supernatant was used for 
measuring the concentration of cytokines (IL-10, TNFα, IL-6, IL-1β, IL-2, IL-17A, 
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IFNγ) by each ELISA kits (eBioscience) according to the manufacturer’s instructions. 
Lysophospholipase D activity of ATX was measured by LysoPLD assay as described 
previously9). Briefly, peritoneal fluid samples were mixed with 14:0 LPC (100 mM 
Tris-HCl, 5 mM MgCl2, 500 mM NaCl, 0.05% Triton X-100, pH 9.0) and incubated 
for 3 h at 37°C. The amount of free choline liberated was determined by a 
colorimetric method, using choline oxidase (Wako, Osaka, Japan), peroxidase 
(TOYOBO, Osaka, Japan) and TOOS reagent (Dojindo, Kumamoto, Japan). The 
activity was indicated by the generation rate of choline amount per sample volume, 
per unit time (pmol/ml/h).  
 
Lipopolysaccharide (LPS) administration-induced sepsis   
Mice were intraperitoneally injected with LPS (E. coli O55:B5, Sigma)). The dose of 
1 mg/kg body weight LPS was used for cytokine analysis. The dose of 30 mg/kg body 
weight of LPS was used to monitor survival. Plasma and peritoneal fluids were 
collected 2 h after LPS injection for measurement of cytokine levels by MAGPIX 
system (Luminex Co.). 
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2.3. In vivo macrophage depletion 
150 µL/body Clophosome®-A-Clodronate Liposomes (Anionic) were 
intraperitoneally injected 24 h before CLP induction or LPS injection for macrophage 
depletion. Success of depletion was confirmed by staining with APC Anti-Mouse 
F4/80 Antigen (clone: BM8.1, Tonbo Bioscience) and checked by EC800 (Sony) and 
analyzed by FlowJo Software (Tree Star). 
 
2.4. Stimulation of peritoneal cavity cells in vitro  
Naïve peritoneal cells were harvested from adult male mice (8-12 weeks) by injecting 
1mL sterile PBS following a gentle massage and collected by pipette. After 
centrifuged at 300×g for 5 min, cell pellet were resuspended in FCS-free RPMI-1640 
medium (Nissui Pharmaceutical) supplemented with 100 U/ml penicillin 
(Sigma-Aldrich), 100 mg/ml streptomycin (GIBCO) and 1 mM L-glutamine 
(Sigma-Aldrich). To isolate different cell populations in the peritoneal cavity, 
resuspended cells were first incubated with anti-CD16/32 (clone: 2.4G2, Tonbo 
Bioscience) to block nonspecific binding, then stained with APC Anti-Mouse F4/80 
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Antigen (clone: BM8.1, Tonbo Bioscience), FITC Anti-Mouse CD3e (clone: 
145-2C11, Tonbo Bioscience) and PE Anti-Mouse CD19 (clone: 1D3, Tonbo 
Bioscience) and sorted by SH800 (Sony). 1×105 cells were transferred to 96-well ﬂat 
bottom culture plates along with 10 ng/mL LPS and LPA with concentration indicated 
in each experiment. Supernatant were collected for IL-10 measurement after 4 h 
stimulation.  
 
2.5. Mouse recombinant IL-10: cloning, expression and purification 
Total RNAs from mice peritoneal cavity cells were isolated using GenElute 
Mammalian Total RNA Miniprep Kit (Sigma-Aldrich) and cDNA libraries were 
synthesized with a high-capacity cDNA RT Kit (Applied Biosystems). cDNA for 
IL-10 with DNA sequences encoding 6×His tag added at the COOH terminus were 
amplified by nested PCR using the reverse-transcripted cDNA libraries as template. 
The sequences of oligonucleotides used for cloning are as follows: IL-10 1st, 
5’-TGCACTACCAAAGCCACAAGGC-3’ and 
5’-TGCTTCCCAAGGAAGAACCCC-3’, IL-10 2nd, 
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5’-AATTGAGCTCCCGGGTACCGGCCACCATGCCTGGCTCAGCACT-3’ and 
5’-CAGGGCATTGGCCATCGATCTTAGTGGTGGTGGTGGTGGTGGCTTTTCA
TTTTGATCATCATGTAT-3’. The resulting DNA fragments were subcloned into a 
pCAGGS vector, and then transformed to E.coli to extract and purify IL-10 DNA 
plasmid. IL-10 DNA plasmid were transfected into HEK293 cells, which were grown 
in Dulbecco's modified Eagle medium (DMEM) containing 10% fetal calf serum 
(FCS), 100 U/mL penicillin, 100 µg/mL streptomycin and 1 mM L-glutamine, using 
polyethylenimine (PEI). Culture medium were concentrated with centrifugal filter 
(Centricon® Plus-70 Centrifugal Filter Units, 10 kDa NMW), and purified on column 
filled with Ni-NTA Agarose (QIAGEN). The amount of prepared IL-10 was 
measured by ELISA. 
 
2.6. LC-MS/MS analysis  
Quantification of lysophospholipids by LC-MS/MS was performed as previously 
described21). Briefly, lipid extraction from peritoneal fluids was performed by 
one-step methanol precipitation containing 17:0 LPA (final concentration 100 nM) 
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and 17:0 LPC (final concentration 1 µM) as internal standard. After centrifugation, 
the supernatants were ﬁltered through a 0.2 µm ﬁlter and subjected to LC-MS/MS. 
The LC-MS/MS system is consisted of an Ultimate 3000 HPLC and a TSQ Quantiva 
triple-quadrupole mass spectrometer (Thermo Fisher Scientiﬁc). Analysis of LPC was 
performed with multiple reactive monitoring (MRM) in positive mode. Other species 
of lysophospholipids were analyzed in negative mode.     
 
2.7. Quantitative RT-PCR analysis  
Total RNA from peritoneal cavity cells were extracted by GenElute Mammalian Total 
RNA Miniprep kit (Sigma-Aldrich). Reverse transcription were performed with a 
high-capacity cDNA RT Kits (Applied Biosystems) according to the manufacturer's 
instructions. PCR reactions were carried out using SYBR Premix Ex Taq II (Takara 
Bio) and were monitored by ABI Prism 7300 (Applied Biosystems). Standard 
plasmids ranging from 103 to 107 copies per well were used to quantify the absolute 
number of transcripts of cDNA samples. The numbers of transcripts were normalized 
to the number of a house-keeping gene, Gapdh, in the same sample. PCR was 
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performed using the following primers: 5’-AGGAGCGAGACCCCACTAAC-3’ and 
5’-CGGAGATGATGACCCTTTTG-3’ for Gapdh; 
5’-GCATTAAGGAGTCGGTTAGCAGT-3’ and 
5’-AGTACAGCCGGGAAGACAATAA-3’ for Il10 
5’-AGGAGGAATCGGGACACCA-3’ and 5’-AGCACACATCCAGCAATAACAA 
-3’ for Lpar1; 5’-TGCCGCTTGACTGGATGT-3’ and 
5’-GCTCCTTGCCGCTGTTATT-3’ for Lpar2; 
5’-ACCAACGTCTTATCTCCACACAC-3’ and 
5’-CAGCAGCAGAACCACCAGAC-3’ for Lpar3; 
5’-TCTCTGATCGTCTGCCTCCA-3’ and 5’-GTGCAGGGGTTCACCACTCTT-3’ 
for Lpar4; 5’-CTGTAAGGTGGGTGTGTCAGG-3’ and 
5’-AGACCTGTGATCGGTTGCTC-3’ for Lpar5; 
5’-TGTGCCCTACAACATCAACCT-3’ and 5’-CAAAGCAGCAGTTGGAAACA-3’ 
for Lpar6.  
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2.8. Statistical analysis 
Survival data were analyzed by the log-rank test. The significance of differences 
between groups was determined by Student's t-test.    
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Chapter 3. Protective effects of ATX-LPA in sepsis through IL-10 
3.1. Introduction 
Sepsis is a leading cause of mortality in intensive care units. Systemic inflammatory 
response syndrome (SIRS), the terminology for the imprecise clinical diagnostic term 
‘sepsis’, is defined as the host’s inflammatory response to infection. The latest 
definition of sepsis in 2016 is the life-threatening organ dysfunction caused by a 
dysregulated host response to infection1). Immune response triggered by the invading 
pathogen activated immune cells and other host cells that release pro-inflammatory 
and anti-inflammatory mediators and be implicated in the pathogenesis of sepsis2,3). 
During the initiation phase of inflammation, cytokine storm is induced. 
Pro-inflammatory cytokines such as tumour necrosis factor (TNF), interleukin‑1β 
(IL‑1β), IL‑12 and IL‑18 are implicated in sepsis pathogenesis. Antibodies to block 
these cytokines confer protection in sepsis4,5). On the other hand, IL-10, the prototype 
of anti-inflammatory cytokine, has a dominant protective effect in animal model of 
sepsis22-25).   
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Metabolic derangements are presented in patients with sepsis, especially fatty acid 
metabolism are important in affecting survival on sepsis26). Increase of various fatty 
acids including PC was detected in sepsis patients27). Fatty acids are one of the targets 
of various mediators for treatment of sepsis. Since LPC, the main substrate for LPA 
production, has therapeutic effects in sepsis and its mechanism is still unknown, we 
hypothesized that LPA mediates the protective effects of LPC in sepsis. Furthermore, 
in order to understand the pathological function of endogenous lysophospholipids, the 
changes of lipids were measured by LC-MS/MS. 
 
  
	 23	
3.2. Results 
3.2.1. ATX inhibitor abrogated the protective effects of LPC in CLP-induced 
sepsis 
CLP was performed on C57BL6/J adult male mice, as described in Methods. The 
effects of LPC injection on CLP-induced sepsis were studied as reported previously6). 
Intraperitoneally injected 18:1 LPC at 6 h, 12 h, 24 h, 36 h and 48 h after CLP 
provided slight protection against sepsis-induced lethality. Interestingly, this 
LPC-provided slight protection was abrogated completely by ATX inhibitor 
(ONO-8430506) daily administration (P<0.01) and ATX inhibitor induced severe 
sepsis as judged by the survival rate (Fig.1), suggesting the possibility of 
ATX-dependently produced endogenous LPA in protection against CLP-induced 
sepsis.  
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Figure 1. Abrogated protective effects of LPC in CLP-induced sepsis by ATX 
inhibitor. CLP mice were intraperitoneally injected with 18:1 LPC at 6 h, 12 h, 24 h, 
36 h and 48 h after surgery. ATX inhibitor (ONO-8430506) was orally administrated 
daily at the dose of 100 mg/kg mice body. Survival was monitored for 7 d. n=10-20 
mice per group. 
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3.2.2. Analysis of lysophospholipids amount and ATX activity in peritoneal 
cavity of CLP-subjected mice 
In order to determine the effects of endogenous LPA in sepsis, firstly the levels of 
LPA and other lysophospholipids in CLP model were measured. Peritoneal fluids 
were sampled by 1 mL sterile PBS injection after 2 h, 6 h, 24 h, 48 h, 72 h and 14 d 
after CLP induction. Levels of LPA, LPC and the other lysophospholipids were 
extracted by one-step methanol precipitation and quantified by LC-MS/MS. ATX 
activities of peritoneal fluids were also examined by LysoPLD activity assay. The 
levels of all species of lysophospholipids measured (lysophosphatidic acid, 
lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylinositol, 
lysophosphatidylglycerol and lysophosphatidylserine) that have different polar heads 
were significantly increased at the early stage of 6 h after CLP induction (Fig.2). The 
time-course analysis for LPA and LPC were performed. The increase of LPA and 
LPC started from only 2 h after CLP and returned to a lower level after 2 weeks for 
recovery (Fig.3A, C). Meanwhile, there are much higher activities of ATX in the 
peritoneal fluids from mice subjected to CLP compared with intact mice. The level of 
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ATX activity peaked at 24 h after CLP and returned to the basal level after 14 d 
(Fig.3B). These results suggested that the endogenous LPA in CLP-induced sepsis 
could be produced from the other lysophospholipids, especially LPC, in the ATX 
dependent manner.  
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Figure 2. Increased levels of various lysophospholipids in peritoneal cavity of 
CLP-subjected mice. Peritoneal lavage fluids were collected 6 h after CLP and were 
subjected to LC-MS/MS. Fold changes are shown relative to intact mice. 
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Figure 3. Increased levels LPC, LPA and ATX activity in peritoneal cavity of 
CLP-subjected mice. Time course analysis of LPC, LPA and ATX activity in 
peritoneal lavage fluids in CLP-treated mice. Levels of LPC and LPA were measured 
by LC-MS/MS. ATX activity was measured by LysoPLD activity assay. Data are 
mean±S.D..  
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3.2.3. Effects of ATX inhibitor administration in CLP mice    
To determine whether the increased endogenous LPA in peritoneal cavity of 
CLP-subjected mice is dependent on ATX or not, ATX inhibitor (ONO-8430506) was 
administrated orally at the dose of 100 mg/kg body weight, once a day since mice 
suffered from CLP. ATX activities and LPA levels in peritoneal fluids were examined 
from 6 h to 72 h after CLP (Fig.4A-D). Survival was monitored every 12 h for 7 d 
(Fig.5). Partially reduced ATX activities of peritoneal fluids of CLP mice after ATX 
inhibitor administration were confirmed (Fig. 4A). ATX inhibitor also reduced the 
level of LPA molecules with acyl chains of 18:2 and 20:4 partially (Fig.4C,D). 
However, ATX inhibitor had no effects on the amount of 16:0 LPA (Fig.4B). ATX 
inhibitor administrated mice suffered significantly higher mortality than the control 
group (Fig.5), suggesting that ATX-dependently produced endogenous LPA is 
protective in experimental sepsis. 
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Figure 4. ATX inhibitor partially reduces ATX activity and levels of LPA in 
peritoneal cavity of CLP-subjected mice. CLP mice were orally administrated with 
or without ATX inhibitor. Time course analysis of ATX activity (A) and levels of 
LPA (B-D) in peritoneal lavage fluids were performed.  
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Figure 5. ATX inhibitor leads to higher mortality in CLP-induced sepsis. ATX 
inhibitor (ONO-8430506) was orally administrated once a day since mice suffered 
from CLP. Survival was monitored every 12 h. n=7 mice per group.    
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3.2.4. Effects of LPA treatment in experimental sepsis   
The effects of 18:1 LPA in experimental sepsis were examined. Intraperitoneally 
injected LPA five times at 6 h, 12 h, 24 h, 36 h and 48 h after CLP provided 
significant protection against sepsis-induced lethality (Fig.6A). In contrast, 
subcutaneously injected LPA had no significant effect on the 7-d survival rate in CLP 
mice (Fig.6B), suggesting that it is necessary for LPA to be delivered to the peritoneal 
cavity to exist its function in sepsis. Changes of sepsis-induced cytokine levels 
affected by LPA treatment were also examined. First of all, since LPA is unstable and 
easily be graded in vivo, a stable LPA analogue (T13, 19.08 mg/kg body weight, i.p.) 
was utilized (Fig.7). T13 is one of the ‘T-series’ compounds, which structures are 
similar to 2-acyl-LPA. A ring structure derived from carbohydrates is introduced as 
the scaffold in T-series compounds instead of the glycerol backbone of LPA28). 
Plasma was sampled after LPS and T13 co-injection, and 12 kinds of cytokines were 
measured by MAGPIX system (Fig.7). T13 induced the changes in the level of certain 
cytokines. The anti-inflammatory cytokines IFN-γ, TNF-α and IL-1β were decreased 
(Fig.7). Interestingly, the level of the prototypical anti-inflammatory cytokine IL-10 
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was dramatically increased by T13 (Fig.7). Next, the effects of LPA treatment on 
CLP-induced cytokine levels were also examined. Peritoneal fluids sampled from 
mice that treated with 18:1 LPA (4 mg/kg body weight, i.p.) three times at 6-h 
intervals since mice suffered from CLP. Only very small changes of IL-1β, TNFα, 
IL-17A and IFNγ levels were observed (Fig.8). However, LPA induced the increasing 
of IL-10 level significantly at 6 h after CLP (Fig.8). These findings highlighted the 
possibility of LPA in regulating IL-10 level in sepsis. 
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Figure 6. LPA treatment protects against CLP-induced lethality. (A) CLP mice 
were intraperitoneally injected with 18:1 LPA five times at 6 h, 12 h, 24 h, 36 h and 
48 h after CLP. Survival was monitored for 7 d. n=18 mice per group. (B) CLP mice 
were subcutaneously injected with 18:1 LPA at the same experimental conditions 
with (A). n=7 mice per group.  
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Figure 7. Changes of levels of cytokines induced by a stable LPA analogue in the 
model of LPS-induced sepsis. Time course analysis of levels of IL-10, IFNγ, TNFα, 
IL-1β, RANTES, IL-12p40, IL-17, IL-9, IL-6, MCP-1, IP-10 and IL-12p70 in plasma 
of mice by MAGPIX system after LPS plus LPA analogue (T13) co-injection.  
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Figure 8. Changes of levels of cytokines induced by 18:1 LPA in the model 
CLP-induced sepsis. Time course analysis of levels of IL-10, IL-1β, IL-6, TNFα, 
IL-2, IL-17A and IFNγ by ELISA in plasma of mice treated with 18:1 LPA 6 h, 12 h, 
24 h after CLP. Data are mean±S.D.. *P<0.05 
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3.2.5. Dependency of ATX-LPA on IL-10 to protect against CLP-induced sepsis 
To examine the regulation of IL-10 by ATX, IL-10 level in the peritoneal fluid of 
CLP mice with ATX inhibitor administration was measured. ATX inhibitor 
significantly reduced the high 24-h IL-10 level in peritoneal fluids (Fig.9). Rescue 
experiment with mouse IL-10 recombinant protein was performed next. Mouse IL-10 
recombinant protein was prepared and purified as described in Methods. The activity 
was confirmed by using it to rescue CLP-induced lethality with the same effect at the 
same dose as reported24) (Fig.10A). 3µg/body of mouse IL-10 recombinant protein 
was injected subcutaneously once at 6 h after surgery to ATX inhibitor 
daily-administrated CLP mice. ATX inhibitor-induced sever sepsis, which has higher 
mortality, was rescued by IL-10 recombinant protein (Fig.10B). Proved that the 
protective effect of ATX-LPA axis is working through IL-10. 
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Figure 9. ATX inhibitor reduces the level of IL-10 in peritoneal cavity of 
CLP-subjected mice. CLP mice were administrated with ATX inhibitor. Levels of 
IL-10 in peritoneal lavage fluids 24 h after CLP were measured by ELISA. 
***P<0.001 
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Figure 10. Rescue of the higher mortality in ATX inhibitor treated CLP mice by 
IL-10 recombinant protein. (A) CLP mice were subcutaneously injected once with 1 
or 3 µg/body IL-10 recombinant protein at the timing of 6 h after CLP. n=10-14 mice 
per group. (B) ATX inhibitor daily-administrated CLP mice were subcutaneously 
injected once with 3 µg/body IL-10 recombinant protein at 6 h after surgery. n=10-18 
mice per group.  
0 
20 
40 
60 
80 
100 
0 1 2 3 4 5 6 7 
%
 su
rv
iv
al
 
Days 
ONO-8430506 + rIL-10 
Vehicle 
ONO-8430506 
P<0.05 
0 
20 
40 
60 
80 
100 
0 1 2 3 4 5 6 7 
%
 su
rv
iv
al
 
Days 
3 ug/body rIL-10  
1 ug/body rIL-10 
Vehicle 
A 
B 
	 40	
3.3. Discussion 
All the results of Chapter 3 proved the protective effect of ATX-LPA in experimental 
sepsis, which functions through the prototypical anti-inflammatory cytokine IL-10. 
Firstly, the significant increase of LPA and also other lysophospholipids including 
LPC, which could be the substrates for LPA production29), was observed in the 
peritoneal cavity of CLP mice. It is consistent with previous reports that metabolic 
dysfunctions including alternations in fatty acid metabolism are critical on survival in 
patients with sepsis26). Higher concentrations of PC are observed in sepsis patients27). 
Furthermore, the increase of the lysophospholipase D activity of ATX, which has 
been demonstrated to catalyze the production of LPA from LPC9), was also observed. 
ATX inhibitor (ONO-8430506) inhibited lysophospholipase D activity and LPA 
production in peritoneal fluids of CLP mice. However, the time course of production 
of LPA was not completely consistent with its main substrate LPC and the inhibition 
of lysophospholipase D activity and LPA production by ATX inhibitor are only 
partially. We cannot exclude the possibility that there are other pathways, other than 
	 41	
the ATX-dependent manner, for the production of LPA in the peritoneal cavity in 
sepsis. 
 
Secondly, it is important that ATX inhibitor significantly increased CLP-induced 
mortality, indicates that the endogenous LPA, which produced by ATX is essential 
for survival in sepsis. Both LPA and one stable LPA analogue treatment in CLP 
model and LPS model respectively induced the changes of levels of certain cytokines. 
IFNγ, TNFα and IL-1β were decreased, and IL-10 was increased in LPS model. In 
CLP model, although only slight changes of levels of cytokines were observed, the 
pattern of IL-10 regulation, which increased at the very early stages, was similar to 
LPS model. Targeting of several cytokines has been reported be beneficial to sepsis, 
including the monoclonal antibodies to TNF prevented sepsis4), treated sepsis with 
combining TNFα inhibitor plus antagonist of IL-1β receptor30), and IFNγ KO mice 
are resisted to CLP-induced mortality31), but the clinical trials were not overtly 
successful5). The protective effects of IL-10 in experimental sepsis also have been 
well studied as reported previously22-25). Our findings of the dramatic increase in the 
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level of IL-10 by LPA injection highlighted the relationship between LPA and IL-10 
in sepsis. IL-10 recombinant protein also rescued mice from the severe sepsis caused 
by ATX inhibitor. Thus, ATX-LPA functioned dependent on the anti-inflammatory 
cytokine IL-10 to protect against CLP-induced lethality. Although the dependency 
was confirmed, since IL-10 recombinant protein administration alone is effective 
enough for rescue25), we cannot simply conclude that IL-10 is the direct downstream 
component of ATX-LPA. It will be interesting to look for other possible targets that 
mediating the protective effects ATX- LPA in sepsis. 
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3.4. Conclusion 
In this chapter, the protective effects of ATX dependently produced endogenous LPA 
and the therapeutic effects of LPA administration in experimental sepsis were 
demonstrated. Importantly, the increase of the level of endogenous LPA and the 
activity of its producing enzyme ATX were observed. As far as I am concerned, it is 
first time that someone has proposed and proved the idea that endogenous LPA could 
protect against sepsis in in vivo mice model. IL-10, the prototypical anti-inflammatory 
cytokine that has already been reported to have beneficial effects in sepsis, is 
regulated by LPA endogenously and could rescue the severe sepsis when LPA 
production is inhibited. Thus, the protective effects of ATX-LPA are working through 
IL-10.   
	 44	
Chapter 4. Mechanism of LPA enhanced IL-10 production: mediated 
by LPA5 in peritoneal macrophage 
4.1. Introduction 
To explore the underlying mechanism in more detail, the responsible cell type and the 
involved LPA receptor were examined. Macrophage is a major effector of innate 
immunity and the main population in peritoneal cavity. Previous studies proved the 
protection from experimental sepsis, suppression on TNFα production19) in peritoneal 
macrophage and reduced organ injury20) by exogenous LPA administration. The 
regulations of LPA on LPS-induced maturing dendritic cell capacity including 
cytokines expression32) and on pro-inflammatory phenotypic change of microglia 
through LPA533) are reported. ATX over-expressed microglia also reduced 
LPS-induced pro-inflammatory cytokines production34). However, the mechanism of 
regulation of LPA on IL-10 production is totally unknown.   
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4.2. Results 
4.2.1.Isolated peritoneal macrophage responded to LPA for IL-10 enhancement 
The response of whole peritoneal cavity cells to LPA and LPS co-stimulation was 
examined firstly. Peritoneal cavity cells that harvested from adult male C57BL6/J 
mice were seeded in 96-well plate and added with 10 ng/mL LPS and doses of LPA 
as indicated for 4 h. IL-10 levels in the cell supernatant were increased in a LPA dose 
dependent manner (Fig.11). IL-10 enhancement could not be observed without LPS 
addition, indicated that LPA synergistically induces IL-10 with LPS (Fig.11). Mice 
peritoneal cavity cells were harvested and further sorted by FACS. After staining with 
the distinct markers that specific to macrophage, B cell and T cell, which are the three 
major cell populations in the mouse peritoneal cavity, the isolated cells were 
co-stimulated with LPS with or without LPA for 4 hours. LPA only enhanced IL-10 
production from F4/80 positive cells (Fig. 12). Time-course analysis (1 h, 2 h, 4 h, 8 h 
and 24 h) of both IL-10 mRNA and protein levels of FACS-sorted peritoneal cavity 
cells with LPS and LPA co-stimulation was performed next. LPA-enhanced IL-10 
protein level of F4/80 positive macrophage peaked at 4 hours after stimulation, and 
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IL-10 message RNA level increased at an earlier timing (Fig.13A,B). For the F4/80 
negative cells, there is much less IL-10 induction compared with positive ones 
(Fig.13C,D).  
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Figure 11. Peritoneal cavity cells respond to LPS and LPA co-stimulation to 
induce IL-10 production. Whole peritoneal cavity cells were harvested and 
co-stimulated with LPS plus LPA for 4 h. Levels of IL-10 in supernatant were 
measured by ELISA. Data are mean±S.D.. 
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Figure 12. Isolated peritoneal macrophage responds to LPS and LPA 
co-stimulation for IL-10 induction. Peritoneal cavity cells were harvested, stained 
with anti-F4/80 antibody, anti-CD19 antibody and anti-CD3 antibody, sorted by 
FACS and seeded in 96-well plate. After co-stimulated with LPS and LPA, levels of 
IL-10 in supernatant were measured by ELISA. Data are means±S.D.. 
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Figure 13. Increased IL-10 protein and mRNA levels by LPS and LPA 
co-stimulation of isolated peritoneal macrophage. FACS-sorted F4/80 positive or 
negative cells were co-stimulated with LPS and LPA. Time course measurement of 
levels IL-10 in supernatant was performed by ELISA. Data are means±S.D.. 
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4.2.2. Effects of macrophage in vivo depletion in LPA-enhanced IL-10 production 
To confirm that macrophage is the responsible cell, macrophage in vivo depletion 
with clodronate liposome injection was performed. The success of macrophage 
depletion was confirmed by flow cytometry that no F4/80 positive cell could be 
detected one day after clodronate injection (Fig.14A). The effects of LPA treatment 
on LPS-induced IL-10 levels one day after macrophage depletion were examined. 
LPA enhanced IL-10 levels in both plasma and peritoneal fluids were significantly 
reduced in macrophage depleted LPS-injected mice (Fig.14B,C). The effects of 
macrophage depletion in CLP mice were also examined. LPA-enhanced IL-10 in the 
peritoneal cavity of CLP-subjected mice was also reduced by macrophage depletion 
(Fig.15). 
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Figure 14. In vivo macrophage depletion abrogated LPA induced IL-10 
enhancement in LPS model. Mice were i.p. injected with 150 µL/body 
Clophosome®-A-Clodronate Liposomes (Anionic) 24 h before LPS injection. LPA 
was co-injected with LPS intraperitoneally. Plasma and peritoneal fluids were 
sampled after 2 h. (A) Peritoneal cavity cells were stained with anti-F4/80 antibody 
and analyzed by flow cytometer. Levels of IL-10 in plasma (B) and peritoneal fluids 
(C) were measure by ELISA. *** P<0.001  
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Figure 15. In vivo macrophage depletion abrogated LPA induced IL-10 
enhancement in CLP model. Mice were i.p. injected with 150 µL/body 
Clophosome®-A-Clodronate Liposomes (Anionic) 24 h before CLP. LPA was 
injected at the same time with CLP surgery. Peritoneal fluids were sampled after 6 h 
and levels of IL-10 were measure by ELISA. *P<0.05 
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4.2.3. LPA5 receptor regulated LPA-enhanced IL-10 production 
To investigate which LPA receptor is involved in the LPA-enhanced IL-10 from 
peritoneal macrophage, the expression of six LPA receptors on isolated F4/80+ 
peritoneal macrophage were judged by RT-PCR. Except LPA3 and LPA4, the 
expression other LPA receptors were detectable (Fig.16). Therefore, response to LPS 
and LPA co-stimulation of peritoneal cavity cells from LPA1, LPA2, LPA5 and LPA6 
single knockout mice were examined. Peritoneal cavity cells from LPA5 knockout 
mice significantly reduced IL-10 level when stimulated with LPS and LPA in vitro 
(Fig.17C). IL-10 was not affected by lacking of LPA1 and LPA6 receptors 
(Fig.17A,D). Decreasing tendency of IL-10 production of peritoneal cavity cells from 
LPA2 knockout mice was observed (Fig.17B), but no effect of one LPA2 specific 
agonist (RP-10-83) in enhancing IL-10 production (Fig.18A). The ability and 
specificity of RP-10-83 to LPA2 receptor were already confirmed by the 
TGFα-shedding assay (data not shown), an assay that could sensitively detect GPCR 
activity35). Although there is no LPA5 specific agonist, one of the LPA analogues 
named T19 (Fig.18B), which is more prefer to activate LPA5 receptor but could also 
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and with extremely low affinity to LPA2 (data not shown), enhanced IL-10 production 
comparably to LPA (Fig.18C). A commercial LPA5 antagonist (TC LPA5 4) was also 
examined. The LPA dose-dependently induced IL-10 enhancement was partially 
reduced by TC LPA5 4 (Fig.18D). 
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Figure 16. mRNA expression of LPA receptors in mice peritoneal macrophage. 
qRT-PCR quantification of Lpar1, Lpar 2, Lpar3, Lpar4, Lpar5, and Lpar6 in 
FACS-sorted F4/80+ cells. Data are means±S.D.. ND: not detected. 
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Figure 17. Response of peritoneal cavity cells from each LPA receptor single 
knockout mice to LPA for IL-10 induction. Peritoneal cavity cells harvested from 
LPA1, LPA2, LPA5 and LPA6 single knockout mice were stimulated with LPS and 
LPA for 4 h. Levels of IL-10 in the supernatant were measured by ELISA. Data are 
means±S.D..     
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Figure 18. Effects of LPA receptor agonists and antagonist on IL-10 induction. 
Peritoneal cavity cells were co-stimulated with LPS and LPA2 specific agonist (A), 
LPA analogue T19 (B), LPA plus LPA5 antagonist TC LPA5 4 (C). Levels of IL-10 
in the supernatant after 4 h stimulation were measured by ELISA. Data are means±
S.D.. ***P<0.001 
 
 
 
 
 
 
 
 
 
  
	 59	
4.3. Discussion 
All the experiment data presented in Chapter 4 indicated that LPA enhanced IL-10 
production through LPA5 receptor from mice peritoneal macrophage. Firstly, 
according to the results obtained using the CLP model, all the events observed 
occurred at the very early stages in the peritoneal cavity. Thus, we proposed the 
targets of LPA, at least in part, exist in mice peritoneal cavity. The results showed that 
LPA addition dose dependently increased IL-10 level from the whole peritoneal 
cavity cells of mice. The enhancement could not be observed without LPS 
co-stimulation suggested that LPA synergized with TLR to induce IL-10 production. 
Several co-stimulators have already been reported to reinforce IL-10 production after 
TLR-dependent production36). For instance, the prostaglandin-2 (PGE-2) promoted 
macrophage IL-10 in combination with LPS37,38). Type I IFN is required for 
LPS-induced IL-10 up-regulation39). Vitamin D3 acts synergistically with TLR4 and 
TLR2 to induce IL-10 production in dendritic cells40). These co-stimulators may act 
on different target cells in different patho-physiological conditions. In this study, we 
showed that LPA endogenously promoted IL-10 production in in vivo mice models 
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and functioned as one co-stimulator for inducing IL-10 in peritoneal macrophage.  
 
Secondly, LPA5 receptor was identified as the responsible receptor for LPA-enhanced 
IL-10 production. LPA5 mRNA, together with LPA1, LPA2 and LPA6, is expressed in 
peritoneal macrophage. LPA could not induce IL-10 in the peritoneal macrophage of 
LPA5 knockout mice. In contrast, there is no influence on IL-10 production of 
peritoneal macrophage from LPA1 and LPA6 single knockout mice suggesting that 
LPA1 and LPA6 are not related to the induction of IL-10 by LPA. Moreover, although 
IL-10 level showed decreasing tendency in peritoneal macrophage derived from LPA2 
knockout mice, no response observed using one LPA2 specific agonist. This finding 
suggests that it may be due to the changes of the characteristics of peritoneal cavity 
cells, not through LPA2 receptor. The results of inducing the anti-inflammatory 
cytokine IL-10 in this study is contradictory to the previous report that LPA promotes 
M1-like phenotypic change of microglia, characterized by the production of 
pro-inflammatory cytokines, through LPA5 receptor33). However, the differences may 
simply due to the different experimental condition that LPS is used for co-stimulation 
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in this study. The protective effects of LPA have been reported in several 
LPS-induced inflammatory models15-20). Thus, in pathological conditions, the 
endogenous LPA5 receptor may function protectively. In addition, it was reported that 
LPA5 negatively regulates B cell activation and inhibits Ab response in vivo41). LPA5 
suppresses CD8 T cells activation and LPA5-deficient tumor-specific CD8 T cells are 
better at controlling tumor growth in vivo42). Thus, it is reasonable to assume that 
LPA5 mediates the inhibition of immune responses in various immune cells including 
macrophage. 
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4.4. Conclusion 
In this chapter, the precise mechanism for the phenomenon observed in vivo was 
investigated in more detail. Peritoneal macrophage, rather than other cell populations 
in mice peritoneal cavity, was identified as the target cell by both using the isolated 
pure macrophage in vitro and macrophage depletion in vivo. LPA5 receptor, which 
expressed in peritoneal macrophage, was the involved receptor for LPA-enhanced 
IL-10 production as confirmed with LPA5 knockout mice, LPA5 receptor agonist and 
antagonist.    
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Chapter 5. Summary 
In this study, we observed the high levels of various lysophospholipids including LPA 
by LC-MS/MS in the peritoneal cavity of CLP-subjected mice. The activity of 
LPA-producing enzyme, ATX was also increased significantly. The increased 
endogenous LPA in sepsis could be reduced after ATX inhibitor administration. ATX 
administration also induced severe sepsis with lower survival rate. On the other hand, 
the intraperitoneal injection of LPA protected against sepsis-induced lethality. After 
measuring the changes of cytokines level with direct LPA injection in CLP-subjected 
mice, the dramatic increasing of IL-10 was observed. ATX inhibitor administration 
reduced IL-10 in vivo, and the ATX inhibitor-induced sever sepsis could be rescued 
by recombinant IL-10 protein. Proved the protective effect of ATX-LPA-IL-10 in 
sepsis. In addition, peritoneal macrophage was identified as the responsible cell for 
LPA-enhanced IL-10 production since LPS and LPA co-stimulated FACS-sorted 
F4/80+ cell showed high IL-10 level. The macrophage depletion in vivo by clodronate 
also abrogated IL-10. Furthermore, peritoneal cavity cells that harvested from LPA5 
KO mice, rather than other LPA receptor KO mice, canceled the response. The 
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possibility of LPA5 as the involver receptor was further confirmed with high IL-10 
induced by LPA5 agonist and canceled LPA response by LPA5 antagonist. 
 
In conclusion, we have demonstrated the protective effects of ATX dependently 
produced endogenous LPA in experimental sepsis. It functioned through enhancing 
IL-10 induction from peritoneal macrophage mediated by LPA5 receptor. (Fig.19)  
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Figure 19. Proposed model for LPA-provided protection against sepsis through 
ATX-LPA5-IL-10 axis. LPA is produced in the ATX-dependent manner in the 
peritoneal cavity when sepsis occurred. LPA5 activation in peritoneal macrophage 
synergistically with PAMPs reinforces IL-10 production and protects against 
sepsis-induced lethality.   
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